Results 51 to 60 of about 49,482 (293)
Journal of Translational MedicineBackground Chimeric antigen receptor natural killer (CAR-NK) cells represent a promising advancement in CAR cell therapy, addressing limitations observed in CAR-T cell therapy.
Na Yang +11 more
doaj +1 more source
Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies. [PDF]
, 2018 Polyneuropathy with immunoglobulin M (IgM) monoclonal gammopathy is the most common paraproteinemic neuropathy, comprising a clinicopathologically and immunologically distinct entity.
Dalakas, Marinos
core +2 more sources
Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting
Molecular Oncology, EarlyView.CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia +9 more
wiley +1 more source
The Influence of B Cell Depletion Therapy on Naturally Acquired Immunity to Streptococcus pneumoniae
Frontiers in Immunology, 2021 The anti-CD20 antibody Rituximab to deplete CD20+ B cells is an effective treatment for rheumatoid arthritis and B cell malignancies, but is associated with an increased incidence of respiratory infections.
Giuseppe Ercoli +8 more
doaj +1 more source
B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis. [PDF]
, 2009 The approach to treating autoimmune disorders is currently undergoing a significant change in focus. As therapies are developed that are more precise in targeting the pathogenesis for these diseases, patients experience significantly fewer side effects ...
Sands, Jacob, Tuscano, Joseph M
core +2 more sources
Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use [PDF]
Human Gene Therapy, 2017 The clinical success of gene-engineered T cells expressing a chimeric antigen receptor (CAR), as manifested in several clinical trials for the treatment of B cell malignancies, warrants the development of a simple and robust manufacturing procedure capable of reducing to a minimum the challenges associated with its complexity.
Lock, Dominik +14 more
openaire +2 more sources
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Neuromyelitis Optica Spectrum Disorder (NMOSD) is a chronic autoimmune neuroinflammatory disease, typically characterized by antibodies against aquaporin 4 (AQP4‐IgG) or myelin oligodendrocyte glycoprotein (MOG‐IgG). Simultaneous seropositivity for both antibodies in a single patient is exceedingly rare.
Yeting Luo, Shuhua Xie, Xianghong Liu
wiley +1 more source
Annus Mirabilis - a guide to the 6th European Lupus meeting 3-5 March 2005 [PDF]
, 2005 This article has no ...
Bowman, S.J. +4 more
core
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin +11 more
wiley +1 more source
Frontiers in ImmunologyObjectiveWhile observational studies link immune cells with post-stroke functional outcome, the underlying immune mechanisms are not well understood.
Weiming Sun +16 more
doaj +1 more source